Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Celularity (CELU) EPS (Weighted Average and Diluted) (2020 - 2025)

Celularity (CELU) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.85 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 44.07% year-over-year to -$0.85; the TTM value through Dec 2025 reached -$3.59, down 35.47%, while the annual FY2025 figure was -$3.59, 35.98% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.85 in Q4 2025 for Celularity, up from -$0.88 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.02 in Q4 2022 and bottomed at -$4.98 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.95, with a median of -$0.73 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) soared 115.87% in 2021 and then plummeted 16700.0% in 2023.
  • Celularity's EPS (Weighted Average and Diluted) stood at $0.51 in 2021, then skyrocketed by 100.0% to $1.02 in 2022, then decreased by 17.65% to $0.84 in 2023, then crashed by 170.24% to -$0.59 in 2024, then plummeted by 44.07% to -$0.85 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.85, -$0.88, and -$1.02 for Q4 2025, Q3 2025, and Q2 2025 respectively.